To ask the Secretary of State for Health and Social Care, what guidance he has provided to regulatory and health authorities on ensuring that the UK remains an attractive place to conduct clinical trials and supply human medicines.
Answered on
29 May 2020
The Department is working directly with the Medicines and Healthcare products Regulatory Agency, Health Research Authority, NHS England and NHS Improvement, the National Institute for Health Research and other partners across the health and life sciences sectors to ensure that the United Kingdom remains an attractive place to conduct clinical trials and supply human medicines.
The Medicines and Medical Devices Bill provides the UK the means to remain a world-leading regulator and an important market for medicines and medical devices and supports the delivery of the Life Sciences Industrial Strategy to make the UK a leading global hub for life sciences. The Bill makes clear the importance of ensuring the UK is an attractive place to bring new products to market and conduct clinical trials, specifying that before making any regulations under the Bill, the Secretary of State must consider this point.
We are determined to maintain the UK’s position as one of the best locations globally to run clinical trials.